Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis

Standard cytotoxic chemotherapy for Hodgkin Lymphoma (HL) has changed little in 30 years; the treatment for patients with relapsed or refractory disease remains challenging and novel agents are under development. JAK/STAT constitutive activation plays an important role in the pathogenesis of HL. Les...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz, Tania, Navarro, Alfons, Ferrer, Gerardo, Gel, Bernat, Gaya, Anna, Artells, Rosa, Bellosillo, Beatriz, Garcia-Garcia, Mar, Serrano, Sergi, Martínez, Antonio, Monzo, Mariano
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080386/
https://www.ncbi.nlm.nih.gov/pubmed/21533094
http://dx.doi.org/10.1371/journal.pone.0018856
_version_ 1782202113161428992
author Diaz, Tania
Navarro, Alfons
Ferrer, Gerardo
Gel, Bernat
Gaya, Anna
Artells, Rosa
Bellosillo, Beatriz
Garcia-Garcia, Mar
Serrano, Sergi
Martínez, Antonio
Monzo, Mariano
author_facet Diaz, Tania
Navarro, Alfons
Ferrer, Gerardo
Gel, Bernat
Gaya, Anna
Artells, Rosa
Bellosillo, Beatriz
Garcia-Garcia, Mar
Serrano, Sergi
Martínez, Antonio
Monzo, Mariano
author_sort Diaz, Tania
collection PubMed
description Standard cytotoxic chemotherapy for Hodgkin Lymphoma (HL) has changed little in 30 years; the treatment for patients with relapsed or refractory disease remains challenging and novel agents are under development. JAK/STAT constitutive activation plays an important role in the pathogenesis of HL. Lestaurtinib is an orally bioavailable multikinase inhibitor that has recently been shown to inhibit JAK2 in myeloproliferative disorders. The potential role of Lestaurtinib in HL therapy is unknown. We have analyzed the effect of Lestaurtinib treatment in five HL cell lines from refractory patients, L-428, L-1236, L-540, HDML-2 and HD-MY-Z. At 48 h, a dose-dependent cell growth inhibition (23%–66% at 300 nM) and apoptotic increment (10%–64% at 300 nM) were observed. Moreover, Lestaurtinib inhibited JAK2, STAT5 and STAT3 phosphorylation and reduced the mRNA expression of its downstream antiapoptotic target Bcl-xL. In addition, we have analyzed the effect of Lestaurtinib treatment in lymph nodes from four classic HL patients. We observed a decrease in cell viability at 24 hours of treatment in three patients (mean decrease of 27% at 300 nM). Our findings provide, for the first time, a molecular rationale for testing JAK2 inhibitors, specifically Lestaurtinib, in HL patients.
format Text
id pubmed-3080386
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-30803862011-04-29 Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis Diaz, Tania Navarro, Alfons Ferrer, Gerardo Gel, Bernat Gaya, Anna Artells, Rosa Bellosillo, Beatriz Garcia-Garcia, Mar Serrano, Sergi Martínez, Antonio Monzo, Mariano PLoS One Research Article Standard cytotoxic chemotherapy for Hodgkin Lymphoma (HL) has changed little in 30 years; the treatment for patients with relapsed or refractory disease remains challenging and novel agents are under development. JAK/STAT constitutive activation plays an important role in the pathogenesis of HL. Lestaurtinib is an orally bioavailable multikinase inhibitor that has recently been shown to inhibit JAK2 in myeloproliferative disorders. The potential role of Lestaurtinib in HL therapy is unknown. We have analyzed the effect of Lestaurtinib treatment in five HL cell lines from refractory patients, L-428, L-1236, L-540, HDML-2 and HD-MY-Z. At 48 h, a dose-dependent cell growth inhibition (23%–66% at 300 nM) and apoptotic increment (10%–64% at 300 nM) were observed. Moreover, Lestaurtinib inhibited JAK2, STAT5 and STAT3 phosphorylation and reduced the mRNA expression of its downstream antiapoptotic target Bcl-xL. In addition, we have analyzed the effect of Lestaurtinib treatment in lymph nodes from four classic HL patients. We observed a decrease in cell viability at 24 hours of treatment in three patients (mean decrease of 27% at 300 nM). Our findings provide, for the first time, a molecular rationale for testing JAK2 inhibitors, specifically Lestaurtinib, in HL patients. Public Library of Science 2011-04-20 /pmc/articles/PMC3080386/ /pubmed/21533094 http://dx.doi.org/10.1371/journal.pone.0018856 Text en Diaz et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Diaz, Tania
Navarro, Alfons
Ferrer, Gerardo
Gel, Bernat
Gaya, Anna
Artells, Rosa
Bellosillo, Beatriz
Garcia-Garcia, Mar
Serrano, Sergi
Martínez, Antonio
Monzo, Mariano
Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis
title Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis
title_full Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis
title_fullStr Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis
title_full_unstemmed Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis
title_short Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis
title_sort lestaurtinib inhibition of the jak/stat signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080386/
https://www.ncbi.nlm.nih.gov/pubmed/21533094
http://dx.doi.org/10.1371/journal.pone.0018856
work_keys_str_mv AT diaztania lestaurtinibinhibitionofthejakstatsignalingpathwayinhodgkinlymphomainhibitsproliferationandinducesapoptosis
AT navarroalfons lestaurtinibinhibitionofthejakstatsignalingpathwayinhodgkinlymphomainhibitsproliferationandinducesapoptosis
AT ferrergerardo lestaurtinibinhibitionofthejakstatsignalingpathwayinhodgkinlymphomainhibitsproliferationandinducesapoptosis
AT gelbernat lestaurtinibinhibitionofthejakstatsignalingpathwayinhodgkinlymphomainhibitsproliferationandinducesapoptosis
AT gayaanna lestaurtinibinhibitionofthejakstatsignalingpathwayinhodgkinlymphomainhibitsproliferationandinducesapoptosis
AT artellsrosa lestaurtinibinhibitionofthejakstatsignalingpathwayinhodgkinlymphomainhibitsproliferationandinducesapoptosis
AT bellosillobeatriz lestaurtinibinhibitionofthejakstatsignalingpathwayinhodgkinlymphomainhibitsproliferationandinducesapoptosis
AT garciagarciamar lestaurtinibinhibitionofthejakstatsignalingpathwayinhodgkinlymphomainhibitsproliferationandinducesapoptosis
AT serranosergi lestaurtinibinhibitionofthejakstatsignalingpathwayinhodgkinlymphomainhibitsproliferationandinducesapoptosis
AT martinezantonio lestaurtinibinhibitionofthejakstatsignalingpathwayinhodgkinlymphomainhibitsproliferationandinducesapoptosis
AT monzomariano lestaurtinibinhibitionofthejakstatsignalingpathwayinhodgkinlymphomainhibitsproliferationandinducesapoptosis